CRISPR Therapeutics AG Stock price

Equities

CRSP

CH0334081137

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 02:43:29 2024-03-28 pm EDT 5-day change 1st Jan Change
68.2 USD -2.80% Intraday chart for CRISPR Therapeutics AG -8.17% +9.28%
Sales 2024 * 114M Sales 2025 * 404M Capitalization 5.63B
Net income 2024 * -454M Net income 2025 * -381M EV / Sales 2024 * 35.9 x
Net cash position 2024 * 1.55B Net cash position 2025 * 1.39B EV / Sales 2025 * 10.5 x
P/E ratio 2024 *
-12.8 x
P/E ratio 2025 *
-16.5 x
Employees 407
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.37%
More Fundamentals * Assessed data
Dynamic Chart
Mizuho Adjusts Price Target on CRISPR Therapeutics to $99 From $82, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on CRISPR Therapeutics to $48 From $46, Maintains Underweight Rating MT
Wells Fargo Raises Price Target on CRISPR Therapeutics to $70 From $55, Maintains Equal-Weight Rating MT
Barclays Raises Price Target on CRISPR Therapeutics to $80 From $61, Maintains Equal-Weight Rating MT
Chardan Ups Price Target on CRISPR Therapeutics to $112 From $110, Keeps Buy Rating MT
RBC Raises Price Target on CRISPR Therapeutics to $66 From $57 on Strengthened Balance Sheet, Casgevy Approval; Sector Perform, Speculative Risk Kept MT
Transcript : CRISPR Therapeutics AG Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-21-2024 10:00 AM
Needham Adjusts CRISPR Therapeutics' Price Target to $90 From $88, Keeps Buy Rating MT
CRISPR Therapeutics Swings to Q4 Profit, Revenue Increases MT
CRISPR Therapeutics AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q4 Revenue $201.2M MT
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Posts Q4 EPS $1.10 MT
CRISPR Therapeutics AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Crispr Therapeutics Ag Insider Sold Shares Worth $1,607,177, According to a Recent SEC Filing MT
Wolfe Research Starts Coverage on CRISPR Therapeutics With Peer Perform Rating MT
More news
1 day-1.14%
1 week-3.81%
Current month-16.69%
1 month-21.27%
3 months+8.00%
6 months+48.86%
Current year+12.08%
More quotes
1 week
68.88
Extreme 68.88
74.59
1 month
68.88
Extreme 68.88
89.88
Current year
58.29
Extreme 58.29
91.10
1 year
37.55
Extreme 37.55
91.10
3 years
37.55
Extreme 37.55
169.76
5 years
32.30
Extreme 32.3
220.20
10 years
11.63
Extreme 11.63
220.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 15-07-31
Director of Finance/CFO 40 23-03-13
Chief Tech/Sci/R&D Officer 67 19-09-30
Members of the board TitleAgeSince
Director/Board Member 66 20-06-10
Director/Board Member 46 15-04-28
Director/Board Member 47 15-03-31
More insiders
Date Price Change Volume
24-03-28 68.4 -2.51% 1 166 732
24-03-27 70.16 -1.14% 1,340,687
24-03-26 70.97 -0.15% 835,997
24-03-25 71.08 -0.74% 909,468
24-03-22 71.61 -3.88% 1,024,384

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
70.16 USD
Average target price
88.08 USD
Spread / Average Target
+25.55%
Consensus
  1. Stock
  2. Equities
  3. Stock CRISPR Therapeutics AG - Nasdaq